[{"id":"70fc40e8-2780-469a-93b2-3e3f813f0994","acronym":"BaseTIL-03M","url":"https://clinicaltrials.gov/study/NCT05869539","created_at":"2023-05-22T16:05:47.092Z","updated_at":"2025-02-25T13:55:13.470Z","phase":"Phase 1","brief_title":"ACT-TIL and ANV419 for Advanced Melanoma.","source_id_and_acronym":"NCT05869539 - BaseTIL-03M","lead_sponsor":"University Hospital, Basel, Switzerland","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ANV419"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 06/21/2023","start_date":" 06/21/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2025-02-20"},{"id":"64c0b82c-66f6-4d94-aa8b-d3aaadbb12dc","acronym":"ANV419-001","url":"https://clinicaltrials.gov/study/NCT04855929","created_at":"2023-07-03T20:09:06.191Z","updated_at":"2024-07-02T16:35:19.786Z","phase":"Phase 1","brief_title":"A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients With Advanced Cancer.","source_id_and_acronym":"NCT04855929 - ANV419-001","lead_sponsor":"Anaveon AG","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 overexpression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Yervoy (ipilimumab) • ANV419"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 05/25/2021","start_date":" 05/25/2021","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 01/01/2025","study_completion_date":" 01/01/2025","last_update_posted":"2024-02-12"},{"id":"68f2972e-8669-4ad3-868c-69f2477d1d11","acronym":"OMNIA-1","url":"https://clinicaltrials.gov/study/NCT05578872","created_at":"2022-10-13T17:58:21.130Z","updated_at":"2024-07-02T16:35:19.846Z","phase":"Phase 1/2","brief_title":"A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).","source_id_and_acronym":"NCT05578872 - OMNIA-1","lead_sponsor":"Anaveon AG","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600 • BRAF wild-type","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Yervoy (ipilimumab) • ANV419"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 12/16/2022","start_date":" 12/16/2022","primary_txt":" Primary completion: 09/01/2024","primary_completion_date":" 09/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-12"}]